Annals of Epidemiology
Volume 19, Issue 12 , Pages 841-849 , December 2009

Anthropometric Correlates of Insulin-Like Growth Factor 1 (IGF-1) and IGF Binding Protein-3 (IGFBP-3) Levels by Race/Ethnicity and Gender

  • Jessica M. Faupel-Badger

      Affiliations

    • Cancer Prevention Fellowship Program, National Cancer Institute, National Institutes of Health, Bethesda, MD
    • Corresponding Author InformationAddress correspondence to: Jessica M. Faupel-Badger, National Institutes of Health, 6120 Executive Blvd. (EPS), Suite 150E, MSC 7105, Bethesda, MD 20892. Tel: (301) 496-8640. Fax: (301) 480-2669.
    • ,
  • David Berrigan

      Affiliations

    • Division of Cancer Control and Population Sciences, National Cancer Institute, National Institutes of Health, Bethesda, MD
    • ,
  • Rachel Ballard-Barbash

      Affiliations

    • Division of Cancer Control and Population Sciences, National Cancer Institute, National Institutes of Health, Bethesda, MD
    • ,
  • Nancy Potischman

      Affiliations

    • Division of Cancer Control and Population Sciences, National Cancer Institute, National Institutes of Health, Bethesda, MD

Received 29 January 2009 ,Accepted 12 August 2009.

References 

  1. Ogden CL, Carroll MD, Curtin LR, McDowell MA, Tabak CJ, Flegal KM. Prevalence of overweight and obesity in the United States, 1999-2004. Jama. 2006;295:1549–1555
  2. National Cancer Institute Fact Sheet. Obesity and cancer: questions and answers. Bethesda MNCIM, 2004. http://www.cancer.gov/cancertopics/factsheet/Risk/obesity. NCI fact sheet 3.70. Accessed [6/13/2008].
  3. Flegal KM, Graubard BI, Williamson DF, Gail MH. Cause-specific excess deaths associated with underweight, overweight, and obesity. Jama. 2007;298:2028–2037
  4. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003;348:1625–1638
  5. Pan SY, DesMeules M. Energy intake, physical activity, energy balance, and cancer: Epidemiological evidence. In:  Verma M editors. Methods of Molecular Biology, Cancer Epidemiology 472. Totowa, NJ: Humana Press; 2009;p. 191–215
  6. Pan SY, Johnson KC, Ugnat AM, Wen SW, Mao Y. Association of obesity and cancer risk in Canada. Am J Epidemiol. 2004;159:259–268
  7. Giovannucci E, Liu Y, Platz EA, Stampfer MJ, Willett WC. Risk factors for prostate cancer incidence and progression in the health professionals follow-up study. Int J Cancer. 2007;121:1571–1578
  8. Renehan AG, Frystyk J, Flyvbjerg A. Obesity and cancer risk: the role of the insulin-IGF axis. Trends Endocrinol Metab. 2006;17:328–336
  9. Samani AA, Yakar S, LeRoith D, Brodt P. The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr Rev. 2007;28:20–47
  10. Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, et al. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science. 1998;279:563–566
  11. Chan JM, Stampfer MJ, Ma J, Gann P, Gaziano JM, Pollak M, et al. Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer. J Natl Cancer Inst. 2002;94:1099–1106
  12. Stattin P, Rinaldi S, Stenman UH, Riboli E, Hallmans G, Bergh A, et al. Plasma prolactin and prostate cancer risk: A prospective study. Int J Cancer. 2001;92:463–465
  13. Giovannucci E. Insulin, insulin-like growth factors and colon cancer: a review of the evidence. J Nutr. 2001;131:3109S–3120S
  14. Ma J, Pollak M, Giovannucci E, Chan JM, Tao Y, Hennekens C, et al. A prospective study of plasma levels of insulin-like growth factor I (IGF-I) and IGF-binding protein-3, and colorectal cancer risk among men. Growth Horm IGF Res. 2000;(10 Suppl A):S28–S29
  15. Ma J, Pollak MN, Giovannucci E, Chan JM, Tao Y, Hennekens CH, et al. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J Natl Cancer Inst. 1999;91:620–625
  16. Lukanova A, Lundin E, Toniolo P, Micheli A, Akhmedkhanov A, Rinaldi S, et al. Circulating levels of insulin-like growth factor-I and risk of ovarian cancer. Int J Cancer. 2002;101:549–554
  17. Peeters PH, Lukanova A, Allen N, Berrino F, Key T, Dossus L, et al. Serum IGF-I, its major binding protein (IGFBP-3) and epithelial ovarian cancer risk: the European Prospective Investigation into Cancer and Nutrition (EPIC). Endocr Relat Cancer. 2007;14:81–90
  18. Renehan AG, Egger M, Minder C, O'Dwyer ST, Shalet SM, Zwahlen MIGF-I. IGF binding protein-3 and breast cancer risk: comparison of 3 meta-analyses. Int J Cancer. 2005;115:1006–1007
  19. Renehan AG, Harvie M, Howell A. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and breast cancer risk: eight years on. Endocr Relat Cancer. 2006;13:273–278
  20. Allen NE, Appleby PN, Kaaks R, Rinaldi S, Davey GK, Key TJ. Lifestyle determinants of serum insulin-like growth-factor-I (IGF-I), C-peptide and hormone binding protein levels in British women. Cancer Causes Control. 2003;14:65–74
  21. DeLellis K, Rinaldi S, Kaaks RJ, Kolonel LN, Henderson B, Le Marchand L. Dietary and lifestyle correlates of plasma insulin-like growth factor-I (IGF-I) and IGF binding protein-3 (IGFBP-3): the multiethnic cohort. Cancer Epidemiol Biomarkers Prev. 2004;13:1444–1451
  22. Gapstur SM, Kopp P, Chiu BC, Gann PH, Colangelo LA, Liu K. Longitudinal associations of age, anthropometric and lifestyle factors with serum total insulin-like growth factor-I and IGF binding protein-3 levels in Black and White men: the CARDIA Male Hormone Study. Cancer Epidemiol Biomarkers Prev. 2004;13:2208–2216
  23. Gram IT, Norat T, Rinaldi S, Dossus L, Lukanova A, Tehard B, et al. Body mass index, waist circumference and waist-hip ratio and serum levels of IGF-I and IGFBP-3 in European women. Int J Obes (Lond). 2006;30:1623–1631
  24. Henderson KD, Goran MI, Kolonel LN, Henderson BE, Le Marchand L. Ethnic disparity in the relationship between obesity and plasma insulin-like growth factors: the multiethnic cohort. Cancer Epidemiol Biomarkers Prev. 2006;15:2298–2302
  25. Lukanova A, Lundin E, Zeleniuch-Jacquotte A, Muti P, Mure A, Rinaldi S, et al. Body mass index, circulating levels of sex-steroid hormones, IGF-I and IGF-binding protein-3: a cross-sectional study in healthy women. Eur J Endocrinol. 2004;150:161–171
  26. Lukanova A, Soderberg S, Stattin P, Palmqvist R, Lundin E, Biessy C, et al. Nonlinear relationship of insulin-like growth factor (IGF)-I and IGF-I/IGF-binding protein-3 ratio with indices of adiposity and plasma insulin concentrations (Sweden). Cancer Causes Control. 2002;13:509–516
  27. Platz EA, Pollak MN, Rimm EB, Majeed N, Tao Y, Willett WC, et al. Racial variation in insulin-like growth factor-1 and binding protein-3 concentrations in middle-aged men. Cancer Epidemiol Biomarkers Prev. 1999;8:1107–1110
  28. Berrigan D, Potischman N, Dodd KW, Hursting SD, Lavigne J, Barrett JC, et al. Race/ethnic variation in serum levels of IGF-I and IGFBP-3 in US adults. Growth Horm IGF Res. 2008;
  29. National Center for Health Statistics . NCHS plan and operation of the Third National Health and Nutrition Examination Survey, 1988-1994. Vital Health Stat. 1994;1
  30. National Center for Health Statistics. Analytic and reporting guidelines: the Third National Health and Nutrition Examination Survey, NHANES III (1988-1994). Hyattsville, MD, 1996.
  31. Berrigan D, Potischman N, Dodd KW, Nicar M, McQuillan G, Lavigne JA, et al. Serum levels of insulin-like growth factor-1 and insulin like growth factor-1 binding protein-3: Quality control for studies of stored serum. Cancer Epidemiol Biomarkers Prev. 2007;16:1017–1022
  32. Chumlea WC, Guo SS, Kuczmarski RJ, Flegal KM, Johnson CL, Heymsfield SB, et al. Body composition estimates from NHANES III bioelectrical impedance data. Int J Obes Relat Metab Disord. 2002;26:1596–1609
  33. Shah BV, Barnwell G, Bieler GS. SUDAAN user's manual, release 8.0. Research Triangle Park, NC: Research Triangle Institute; 1997;
  34. Korn EL, Graubard BI. Analysis of health surveys. New York: John Wiley and Sons; 1999;
  35. Holmes MD, Pollak MN, Hankinson SE. Lifestyle correlates of plasma insulin-like growth factor I and insulin-like growth factor binding protein 3 concentrations. Cancer Epidemiol Biomarkers Prev. 2002;11:862–867
  36. Chang S, Wu X, Yu H, Spitz MR. Plasma concentrations of insulin-like growth factors among healthy adult men and postmenopausal women: associations with body composition, lifestyle, and reproductive factors. Cancer Epidemiol Biomarkers Prev. 2002;11:758–766
  37. Kaaks R, Lukanova A. Energy balance and cancer: the role of insulin and insulin-like growth factor-I. Proc Nutr Soc. 2001;60:91–106
  38. Gunter MJ, Hoover DR, Yu H, Wassertheil-Smoller S, Manson JE, Li J, et al. A prospective evaluation of insulin and insulin-like growth factor-I as risk factors for endometrial cancer. Cancer Epidemiol Biomarkers Prev. 2008;17:921–929
  39. Gunter MJ, Hoover DR, Yu H, Wassertheil-Smoller S, Rohan TE, Manson JE, et al. Insulin, insulin-like growth factor-I, endogenous estradiol, and risk of colorectal cancer in postmenopausal women. Cancer Res. 2008;68:329–337
  40. Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer. 2004;4:579–591
  41. Frystyk J. Utility of free IGF-I measurements. Pituitary. 2007;10:181–187
  42. Frystyk J. Free insulin-like growth factors–measurements and relationships to growth hormone secretion and glucose homeostasis. Growth Horm IGF Res. 2004;14:337–375
  43. Baur JA, Pearson KJ, Price NL, Jamieson HA, Lerin C, Kalra A, et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature. 2006;444:337–342
  44. Hursting SD, Nunez NP, Varticovski L, Vinson C. The obesity-cancer link: lessons learned from a fatless mouse. Cancer Res. 2007;67:2391–2393
  45. Yakar S, Nunez NP, Pennisi P, Brodt P, Sun H, Fallavollita L, et al. Increased tumor growth in mice with diet-induced obesity: impact of ovarian hormones. Endocrinology. 2006;147:5826–5834
  46. Berrigan D, Perkins SN, Haines DC, Hursting SD. Adult-onset calorie restriction and fasting delay spontaneous tumorigenesis in p53-deficient mice. Carcinogenesis. 2002;23:817–822
  47. Hursting SD, Lashinger LM, Wheatley KW, Rogers CJ, Colbert LH, Nunez NP, et al. Reducing the weight of cancer: mechanistic targets for breaking the obesity-carcinogenesis link. Best Pract Res Clin Endocrinol Metab. 2008;22:659–669
  48. American Cancer Society . Cancer Facts and Figures 2008. Altanta: American Cancer Society; 2008;
  49. Allen NE, Roddam AW, Allen DS, Fentiman IS, Dos Santos Silva I, Peto J, et al. A prospective study of serum insulin-like growth factor-I (IGF-I), IGF-II, IGF-binding protein-3 and breast cancer risk. Br J Cancer. 2005;92:1283–1287
  50. Giovannucci E, Pollak MN, Platz EA, Willett WC, Stampfer MJ, Majeed N, et al. A prospective study of plasma insulin-like growth factor-1 and binding protein-3 and risk of colorectal neoplasia in women. Cancer Epidemiol Biomarkers Prev. 2000;9:345–349
  51. Renehan AG, Zwahlen M, Minder C, O'Dwyer ST, Shalet SM, Egger M. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet. 2004;363:1346–1353
  52. Stattin P, Bylund A, Rinaldi S, Biessy C, Dechaud H, Stenman UH, et al. Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk: a prospective study. J Natl Cancer Inst. 2000;92:1910–1917

PII: S1047-2797(09)00301-9

doi: 10.1016/j.annepidem.2009.08.005

Annals of Epidemiology
Volume 19, Issue 12 , Pages 841-849 , December 2009

Article Tools